David A. Rewolinski

773 citations
7 papers · 638 indexed · 1 hit paper · h-index 6
Topics
Enzyme function and inhibition (2 papers)Retinal Diseases and Treatments (2 papers)Cholinesterase and Neurodegenerative Diseases (2 papers)
Partner nations
United States

In The Last Decade

David A. Rewolinski

7 papers receiving 625 citations

Hit Papers

Nonclinical Antiangiogenesis and Antitumor Activities of ...20082026201420202008100200300400500

Peers

David A. Rewolinski
Comparison fields: 5 of 78
  • Molecular Biology 355
  • Pulmonary and Respiratory Medicine 249
  • Oncology 209
  • Cancer Research 136
  • Organic Chemistry 74
Replace Anna Fioravanti with:
Anna Fioravanti Italy
Andrea H. Epperly United States
Maren L. Grazzini United States
Ming‐Chih Crouthamel United States
Steve Bender United States
Max Hallin United States
Amogh Boloor United States
Teresa Di Desidero Italy
Lisa Malburg United States
Eiji Ogawa Japan
David A. Rewolinski relative to Anna Fioravanti Italy Anna Fioravanti's profile →
Citations per field
00.5×1.5×
Anna Fioravanti · 1×
Citations per year

Countries citing papers authored by David A. Rewolinski

Since Specialization
Citations

This map shows the geographic impact of David A. Rewolinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Rewolinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Rewolinski more than expected).

Fields of papers citing papers by David A. Rewolinski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Rewolinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Rewolinski. The network helps show where David A. Rewolinski may publish in the future.

Co-authorship network of co-authors of David A. Rewolinski

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Rewolinski. A scholar is included among the top collaborators of David A. Rewolinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Rewolinski. David A. Rewolinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
#WorkIndexed citations
1 24
2 27
3 39
4
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3breakdown →
515
5 9
6
A Potent and Selective Inhibitor of VEGFR and PDGFR Inhibits Ocular Angiogenesis
1
7 23

About David A. Rewolinski

David A. Rewolinski is a scholar working on Ophthalmology, Pharmacology and Molecular Biology, having authored 7 papers that have together received 638 indexed citations. Recurring topics across this work include Enzyme function and inhibition (2 papers), Retinal Diseases and Treatments (2 papers) and Cholinesterase and Neurodegenerative Diseases (2 papers). The work is most often cited by research in Cancer Research (136 citations), Oncology (209 citations) and Pulmonary and Respiratory Medicine (249 citations). David A. Rewolinski has collaborated with scholars based in United States. Frequent co-authors include Grant Wickman, Dana D. Hu‐Lowe, Michele McTigue, Patrick M. O’Connor, Helen Y. Zou, Max Hallin, Brion W. Murray, Xinglin Wu, Robert S. Kania and Jeffrey H. Chen. Their work appears in journals such as Clinical Cancer Research, Hypertension and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026